Objective To investigate the value of serum antitissue transglutaminase IgA antibodies (IgA-TTG) and IgA antiendomysial antibodies (IgA-EMA) in the diagnosis of coeliac disease in cohorts from different geographical areas in Europe. The setting allowed a further comparison between the antibody results and the conventional smallintestinal histology.
Methods A total of 144 cases with coeliac disease [median age 19.5 years (range 0.9-81.4)], and 127 disease controls [median age 29.2 years (range 0.5-79.0)], were recruited, on the basis of biopsy, from 13 centres in nine countries. All biopsy specimens were re-evaluated and classified blindly a second time by two investigators. IgA-TTG were determined by ELISA with human recombinant antigen and IgA-EMA by an immunofluorescence test with human umbilical cord as antigen.
Introduction
The diagnostic criteria of coeliac disease are based on the finding of small-intestinal mucosal villous atrophy with crypt hyperplasia. Subtle and atypical symptoms often make the diagnosis difficult, and, therefore, serological screening tests have proved essential in the diagnostic approach.
Both IgA antiendomysial antibody (EMA) test and the more recent IgA antitissue transglutaminase (TTG) antibody test have been found to offer a better specificity and sensitivity than IgA class antigliadin test [1, 2] . The IgA-EMA test is relatively laborious and considered more observer-dependent than IgA-TTG, which is therefore the method of choice in the case identification of coeliac disease. However, in some studies, the IgA-TTG test has not been perfect. There are obvious reasons for the divergence between the studies, including differences between the various commercial kits [3] . In addition, not all cases, and especially non-coeliac controls, have always been biopsy proven, the histological interpretation has not been blinded, and the likelihood of coeliac disease has varied in different studies. Cases with apparently falsepositive or false-negative serology may confuse, and it is possible, or even likely, that serological tests have influenced the final diagnosis. To make the issue even more confusing, the value of histology as a gold standard has been questioned [4] .
To overcome these diagnostic difficulties, we carried out a controlled European multicentre study to evaluate the value of IgA antibody measurement to human recombinant TTG in comparison with IgA-EMA in the diagnosis of coeliac disease. All cases and controls were biopsy proven and histological interpretation was done in a strictly blinded manner. This also enabled a comparison of the accuracy of the standard intestinal biopsy with that of serological tests.
Patients and methods

Patients and controls
The study was carried out in 13 European centres and included children and adults. Each centre enrolled biopsy-proven coeliac patients and non-coeliac controls. Blood samples for the serological tests had to be drawn no more than 60 days before and not after the date of small-bowel biopsy, and the patients had to maintain a gluten-containing diet. The exclusion criteria were also applied to individuals who had participated in population-screening studies, and to all whose diagnosis was otherwise primarily based on previous serological screening.
The study comprised 169 patients with coeliac disease and 129 non-coeliac controls, but the final clinic visit showed that 16 patients were adhering at least to a partial gluten-free diet, and in nine patients and two controls the interval between biopsy and serum samples was beyond the appointed limits. The presenting symptoms by the time of the biopsy differed, as expected, between patients and controls ( Table 1) . The controls included individuals with gastrointestinal symptoms, but possible coeliac disease was suspected in those with short stature, weight loss and anaemia. Small-intestinal biopsy was taken routinely. Thus, a total of 144 patients and 127 controls were finally included.
Small-intestinal biopsy
The analysis of intestinal mucosa was made from paraffin blocks stained with haematoxylin-eosin. Two researchers independently analysed the biopsy samples without any knowledge of the original diagnosis; in the case of divergence between the analyses of these two researchers, an agreement on the final histological diagnosis was settled in a separate session. Subtotal or severe partial villous atrophy with crypt hyperplasia was considered compatible with coeliac disease. The quality of biopsy was classified into good, moderate and poor. In a good sample, four to five well-orientated villous crypt pairs had to be found; in moderate samples, the orientation was not complete but two to three diagnostic villi and crypts were seen; and poor samples showed no such areas in which the diagnosis could be made, and were hence considered unacceptable. The clinical history was scrutinized afterwards in cases in which the original diagnosis and the second reading did not agree.
Serological tests
IgA-EMA was determined using human umbilical cord as antigen [1] . The titre 1 : 5 and all subsequent Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Data are numbers (%), unless otherwise specified. Flow diagram of the study. dilution steps were considered positive; the correlation with IgA-EMA test with monkey oesophageal antigen has previously shown to be good [1] .
IgA-TTG was determined with an indirect non-competitive ELISA (Celikey, Pharmacia Diagnostics GmbH, Freiburg, Germany), in accordance with the manufacturer's instructions. Microtitre strips coated with human recombinant TTG were incubated with 100 ìl of each patient's sample diluted 1 : 101. A standard curve with six calibration points was constructed, and positive and negative controls were assayed. Patients' samples, calibrators and controls were assayed in duplicate. Bound IgA was detected with horseradish-peroxidase-conjugated anti-human IgA, and 39395959-tetramethylbenzidine was used as development solution. The colour development was measured in an absorbance reader at 450 nm with a reference wavelength of 620 nm, after adding a stop solution. The standard curve ranged from 0 to 100 U/ml. IgA-TTG concentrations in patients' samples were determined proportionately to the fitted standard curve. Samples with absorbance above the top calibration point were diluted as appropriate and assayed again. The variability of the assay was tested with three serum samples (range 4.3-36.4 U/ml). The within-assay variability had a range of 4.2-7.2%, the between-assay variability was 2.5-2.9% and the total variability was 5.1-7.6%. The detection limit for the assay was 0.1 U/ml and the recommended equivocal range between negative and positive results was 5-8 U/ml.
In antibody-negative coeliac cases in which sufficient serum was available, the presence of selective IgA deficiency was investigated. However, measurement of serum IgA concentration was not possible in all cases due to the limited amount of serum available.
Statistical analysis
Quantitative variables were described in terms of appropriate measures of localization and dispersion; qualitative variables were presented by counts and percentages. The diagnostic performances of IgA-TTG and IgA-EMA were assessed by calculating clinical performance characteristics (i.e. sensitivity and specificity with 95% confidence intervals). A concentration of 6.0 U/ml was used as a cut-off point for IgA-TTG. The evaluations were done using data from all biopsyproven coeliac patients, and non-coeliac controls were used as a reference.
Ethical considerations
The study plan was accepted by the local ethics committees of each participating centre.
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Results
Comparisons between biopsy findings and serological tests
In the second reading, the quality of biopsy samples was considered good in 203 (75%) of 271, and moderate in 39 (14%). In 29 cases (11%) the quality of biopsy samples was so poor that the histological diagnosis could not be verified; clinical characteristics and the probable diagnosis of these 29 are shown in Table 2 . Of coeliac patients, 6% had severe partial and 94% subtotal villous atrophy.
A total of 126 coeliac disease patients and 106 controls were included in the final analysis (Fig. 1) . The results of serological tests are shown in Table 3 for patients in whom the second reading confirmed the initial diagnosis. Overall, IgA-EMA showed a somewhat lower sensitivity and specificity than IgA-TTG, although the difference was not significant. Only one IgA-TTGnegative coeliac patient was IgA-EMA positive. The tests worked as well in small children as in adults, but in children the confidence intervals were wide between the limits, probably due to smaller numbers (Table 3) . Selective IgA deficiency could be excluded in seven of the eight coeliac patients who were negative to both antibodies, and in one case the data were missing.
Divergence between original and second reading
There was disagreement between the initial diagnosis and the second reading in nine (3%) of 271 patients. Four patients in the coeliac group were judged to be non-coeliac, and five controls were diagnosed as having coeliac disease. Clinical data on these patients, who were excluded from the analysis, are shown in Table 4 . In addition, one patient with coeliac disease had initially been enrolled in the wrong group, and was also excluded from further analysis (Fig. 1 ).
Discussion
The cases in this study were enrolled from 13 European countries and included children and adults. Similar to earlier coeliac-screening studies that assessed human recombinant IgA-TTG, this study showed an excellent sensitivity and specificity (Table 5 [ 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] ). There were no significant differences between IgA-EMA or IgA-TTG, but a trend for the advantage of IgA-TTG was evident. Since ELISA IgA-TTG is not as observer dependent and laborious as IgA-EMA, it can be considered the method of choice for coeliacscreening purposes. It is also possible to combine the two tests without significant loss of specificity, but only one coeliac patient in our study would have remained undetected if only IgA-TTG had been used.
Our multicentre study showed that there might be potential pitfalls in different screening studies. First, histological interpretation should be done without any knowledge of the serology. Second, the timing of the testing is essential since some patients may have reduced their gluten intake at the time of serological testing. In this study, the serum samples had to be taken no more than 60 days before the biopsy to avoid spontaneous seroconversion. Samples taken after the biopsy were not allowed, since some patients might try
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. to reduce gluten intake on their own even before the final histological diagnosis. In total, 10% of our cases did not fulfil the criteria above, and most of these patients had started to reduce their gluten intake before serological testing.
Some coeliac cases would have remained undetected due to negative serology, and, therefore, intestinal biopsy must always be considered in cases in which clinical suspicion is high. As to the precision of histology, however, there will be new unexpected difficulties. In current clinical practice, the quality of biopsy samples is obviously not good enough, as was clearly shown in our study. Coeliac disease is often detected before classic symptoms emerge, and, consequently, mucosal damage is not always obvious. Furthermore, the diagnosis is difficult or impossible due to poorly oriented samples (Fig. 2) . We therefore often encounter cases in whom the histological finding is unclear. The problem can be solved partially, but not entirely, by a good quality control and by taking several forceps biopsy specimens.
The position of serology is indisputable in confirming
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the diagnosis of coeliac disease. Due to the high specificity of IgA-EMA and IgA-TTG, some experts believe that small-intestinal biopsy is not always necessary in the diagnosis of coeliac disease [15, 16] . Apart from mucosal architecture and serology, there are also other diagnostic methods in borderline cases. Our recommendations for the diagnostic approach are shown in Table 6 . Coeliac disease is strongly associated with human leucocyte antigens (HLA) DQ2 and DQ8, and the negative predictive value for coeliac disease for patients who share neither of these antigens is over 95% [17] . The HLA DQ analysis is therefore of value in excluding, but not in detecting, coeliac disease. Similarly, immunohistochemical staining of intraepithelial lymphocytes may be helpful in the diagnosis of coeliac disease. The sensitivity and specificity of especially ªä+ T-cell receptor-positive lymphocytes in coeliac disease is better than conventional lymphocyte counts [18, 19] . A different issue occurs in coeliac disease at its early stage and some of our cases with mild atrophy or uncertain histology might have latent coeliac disease. However, this analysis focused on biopsy-proven coeliac disease.
We consider human recombinant IgA-TTG to be the method of choice for screening for coeliac disease, since it provides good sensitivity and specificity. The difficulty in the interpretation of intestinal biopsy makes the role of histology as the stand-alone diagnostic tool questionable. Antibody tests are important, especially in borderline cases, and essential in the diagnostic decision.
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